Sleep Apnea Management

Diagnosis and Classification

The American Academy of Sleep Medicine classifies the severity of OSA based on the Apnea-Hypopnea Index (AHI), with severe OSA defined as an AHI of 30 or more events per hour, as shown in the following severity classification table:
Severity AHI/RDI (events/hour)
No OSA <5
Mild OSA 5-15
Moderate OSA 15-30
Severe OSA ≥30 [1, 2]
The American Academy of Sleep Medicine recommends polysomnography (PSG) as the gold standard for diagnosing severe mixed OSA, measuring multiple parameters including EEG, EOG, EMG, airflow, respiratory effort, and oxygen saturation, with a high level of evidence 1, 3, 2
Important measurements during PSG include Apnea-Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), oxygen desaturation index and nadir, sleep architecture and arousal index, and body position effects, according to the American Academy of Sleep Medicine, with a moderate level of evidence 2, 4

Severe mixed OSA is associated with significant cardiovascular morbidity, including resistant hypertension, increased risk of stroke, cardiac arrhythmias, coronary artery disease, heart failure, and pulmonary hypertension, with a high level of evidence 2
Untreated OSA is associated with increased morbidity (especially cardiopulmonary and metabolic diseases) and increased mortality, and delayed diagnosis increases the risk of cardiovascular complications and mortality, highlighting the importance of accurate and timely diagnosis 1, 5, 2

Perioperative considerations for patients with severe mixed OSA include increased risk of perioperative complications, more difficult airway management, higher sensitivity to sedatives and opioids, and increased risk of postoperative respiratory complications, according to the American Society of Anesthesiologists, with a moderate level of evidence 6
Treatment of severe mixed OSA may require higher CPAP pressures, potentially lower CPAP adherence, and may need bilevel PAP therapy if central components are significant, with a low level of evidence 2
Patients with cardiorespiratory disease, neuromuscular disease, hypoventilation, opioid use, stroke history, or severe insomnia should undergo full polysomnography rather than limited channel testing, as recommended by the American Academy of Sleep Medicine 2
Home sleep testing is suitable for patients with a high pre-test probability of moderate to severe OSA, no significant comorbid conditions, and no suspicion of other sleep disorders, but has limitations in diagnostic capability, as noted by the American Thoracic Society and the American Academy of Sleep Medicine 1, 7, 8, 9, 5

In-laboratory polysomnography (Type I) is the gold standard diagnostic test for sleep disorders, providing the most comprehensive evaluation with the highest diagnostic accuracy, and is essential for complex cases and suspected non-respiratory sleep disorders, as recommended by the American Academy of Sleep Medicine 1, 2
Type II, III, and IV home sleep testing have varying degrees of diagnostic accuracy and limitations, and are not suitable for complex cases or suspected non-respiratory sleep disorders, as noted by the American Thoracic Society and the American Academy of Sleep Medicine 1, 9, 5
Relying solely on questionnaires or screening tools lacks adequate specificity for diagnosis, and night-to-night variability can lead to false negative results on single-night studies, while home sleep testing tends to underestimate AHI compared to in-laboratory PSG, as noted by the American Academy of Sleep Medicine 1, 9, 5, 2